The University of Pennsylvania (UPenn) Cancer Research Training Program is designed to identify and train a next generation of outstanding investigators focused on the problem of human malignancies. The Program provides the protected time, resources, educational experience and environment necessary to achieve this goal, as has been demonstrated throughout the past twenty-one consecutive years of funding. Traditionally focused on emerging physician-scientists, the Program has been highly successful in nurturing these young investigators to productive research careers in basic and clinical cancer research. To meet the increasing demands of our shared translational research mission, we now propose to integrate recently graduated PhD scientists into the Program. The 43 faculty preceptors from the Abramson Cancer Center (ACC) at UPenn were selected from across the translational research spectrum to provide a rich group of potential mentors to all trainees. The modified Training Program will leverage the existing strengths that have been successful in training our physician-scientists, and add new training experiences for PhD trainees. An Executive Committee broadly representative of the research experiences available to our trainees will oversee the Program, including recruitment, evaluation and career development.

Public Health Relevance

Significant advancement towards preventing and curing human cancer relies on quality investigators dedicated to translational science. The Cancer Research Training Program strives to recruit and train the next generation of individuals who will lead the field of cancer research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Richman, Sarah A; Nunez-Cruz, Selene; Moghimi, Babak et al. (2018) High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Cancer Immunol Res 6:36-46
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Huang, Alexander C; Postow, Michael A; Orlowski, Robert J et al. (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60-65
Bosse, Kristopher R; Raman, Pichai; Zhu, Zhongyu et al. (2017) Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell 32:295-309.e12
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82
Wilson, Melissa A; Guld, Kelly; Galetta, Steven et al. (2016) Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer 4:66
Shah, Nirav N; Casella, Erica; Capozzi, Donna et al. (2016) Improving the Safety of Oral Chemotherapy at an Academic Medical Center. J Oncol Pract 12:e71-6
Pauken, Kristen E; Sammons, Morgan A; Odorizzi, Pamela M et al. (2016) Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354:1160-1165
Bosse, Kristopher R; Maris, John M (2016) Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer 122:20-33

Showing the most recent 10 out of 85 publications